ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2019
Bloodstream infections due to carbapenemase-producing Enterobacteriaceae in Italy: results from nationwide surveillance, 2014 to 2017.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 72 citations in OpenAlex.
- Emergence and Dissemination of NDM+OXA-48-like Co-ProducingAntibiotics (Basel, Switzerland) · 2026Article
- Emergence of NDM-5-producing ST405 and NDM-1-producing ST10 Escherichia coli in bloodstream infections in Apulia, Italy, 2023-2025.Scientific reports · 2026Article
- A Seven-Year Study of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2020-2024.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2026Article
- Bloodstream Infections Due to Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2026Review
- Whole-genome sequencing and molecular analysis of carbapenem-resistantFrontiers in microbiology · 2026Article
- Trends in Antimicrobial Resistance at a Greek Tertiary Hospital over a 7-Year Period, Including the COVID-19 Pandemic.Antibiotics (Basel, Switzerland) · 2025Article
- The evolving epidemiology of Carbapenemase-producing Enterobacterales in Canadian acute care facilities, 2010-2023.Antimicrobial resistance and infection control · 2025Article
- Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2019-2023.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2025Article
- The magnitude of MDR carbapenemase-producing Enterobacteriaceae isolates and associated factors among hospitalized patients of Northeast Ethiopia.JAC-antimicrobial resistance · 2025Article
- Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018-2022).European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2024Observational
- Nationwide, population-based observational study of the molecular epidemiology and temporal trend of carbapenemase-producing Enterobacterales in Norway, 2015 to 2021.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2023Observational
- Bloodstream infections and antibiotic resistance patterns: a six-year surveillance study from southern Italy.Pathogens and global health · 2023Article
- Evaluation of the Liquid Colony™ Produced by the FAST System for Shortening the Time of Bacterial Identification and Phenotypic Antimicrobial Susceptibility Testing and Detection of Resistance Mechanisms from Positive Blood Cultures.Diagnostics (Basel, Switzerland) · 2023Article
- Rapid diagnostics and ceftazidime/avibactam for KPC-producing Klebsiella pneumoniae bloodstream infections: impact on mortality and role of combination therapy.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2023Observational
- A Seven-Year Microbiological and Molecular Study of Bacteremias Due to Carbapenemase-ProducingAntibiotics (Basel, Switzerland) · 2022Article
- Microbial epidemiology and clinical risk factors of carbapenemase-producing Enterobacterales amongst Irish patients from first detection in 2009 until 2020.Infection prevention in practice · 2022Article
- Necrotizing fasciitis of the vulva due to carbapenem-resistant Enterobacteriaceae as a complication of acute myeloid leukemia treatment: a case report.Journal of medical case reports · 2022Article
- Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections.The Journal of antimicrobial chemotherapy · 2021Article
- Epidemiology and Pattern of Resistance of Gram-Negative Bacteria Isolated from Blood Samples in Hospitalized Patients: A Single Center Retrospective Analysis from Southern Italy.Antibiotics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the rapid increase of infections due to carbapenemase-producing Enterobacteriaceae (CPE) in Italy, the national surveillance of bloodstream infections (BSI) due to CPE (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.